Six case studies from Auperon's platform work across cell therapy, bioprocessing, and novel biology. Different customers, different questions — same mechanism-level approach.
"How do we optimize our prototype iPSC media to outperform commercial standards — and yield higher-quality HSCs when we later trigger differentiation?"
Why this matters. Generating bona fide, transplantable HSCs from iPSCs remains one of the biggest unsolved problems in regenerative medicine — every mechanism-level optimization at the pre-differentiation stage compounds into the final HSC yield when differentiation is eventually triggered.
Customer: A leading commercial supplier of human cell products for regenerative medicine and cell therapy applications (repeat Auperon customer).
"How do we optimize TIL differentiation and shorten our expansion protocol — without sacrificing therapeutic potential — for precision cancer treatment?"
Why this matters. The FDA's 2024 approval of lifileucel (Amtagvi) — the first cellular therapy approved for any solid tumor — validated TIL therapy for advanced melanoma and opened a path forward for other cancers. But the field faces a persistent tension: shorter expansion protocols mean faster patient access and lower manufacturing costs, while longer protocols risk immune exhaustion, dysfunction, and reduced therapeutic potency. Every day cut from a 22-day manufacturing process is meaningful — for cost, for patient wait time, and for the population of patients TIL therapy can practically reach.
Customer: A leading cell therapy manufacturing center advancing TIL therapy for solid tumor indications. Commercial partner name protected under confidentiality.
"How can multi-omic analysis identify novel media additive candidates that improve viability, expansion, and FOXP3 stability for a cGMP Treg expansion protocol for autologous ulcerative colitis therapy?"
Why this matters. Ulcerative colitis affects millions with debilitating chronic inflammation. Autologous Treg cell therapy represents a promising alternative to lifelong immunosuppression — but the inflammatory milieu of UC specifically downregulates FOXP3 expression, causing Tregs to transdifferentiate into pro-inflammatory effector T cells. Manufacturing a Treg product that maintains stability and function in the gut environment is one of the field's central technical challenges.
Study type: BD-driven Auperon Tier 2 workflow — we ran this analysis on our own capital to demonstrate what mechanism-level insight could contribute to leading Treg cell therapy programs pursuing UC-specific applications.
"How do we optimize our chemically-defined MSC media to match the performance of our serum-containing formulation — and eliminate vacuole formation in a variant showing this issue?"
Why this matters. MSC therapies span 850+ clinical trials in regenerative medicine, but the industry's shift from serum-containing to chemically-defined media remains a critical bottleneck for clinical translation and cost — and figuring out what serum was actually providing that CDM lacked is a mechanism-level question, not an empirical screening one.
Customer: A leading commercial supplier of human MSCs for cell therapy applications.
"Can Auperon's platform surface actionable insights on our novel cell culture system — and identify where to focus optimization to reduce culture variability, extend viable culture duration, and improve developmental outcomes?"
Why this matters. Stem-cell-derived embryo models are opening new territory in developmental biology, disease modeling, and regenerative medicine — but variability in starting material, viable culture duration, and reproducibility remain fundamental barriers to broader use.
Customer: A pioneering biotech developing next-generation stem cell platforms for regenerative medicine.
Initial: "Can we identify targets that would improve T cell / Treg manufacturing from public data alone?"
Sharpened: "Can we surface novel FOXP3 regulators and growth factor candidates as viable media additives?"
Why this matters. Regulatory T cell therapies represent a fast-growing frontier — the market is projected to grow from $22M in 2025 to $442M by 2035 across autoimmune diseases, transplant rejection, and inflammatory conditions. With 69+ active Treg clinical trials and 90+ companies pursuing this modality, the central manufacturing challenge is well-known: FOXP3 stability. Induced Tregs readily lose FOXP3 expression and revert to conventional T effector cells. Ex vivo expanded Tregs show poor survival post-transfer. Standard expansion protocols yield highly variable fold expansion. The field needs better media.
Study type: Public dataset study demonstrating Auperon Tier 1 workflow.
Fixed scope. Fixed price. Fixed timeline. Discovery starts at $9,900.